Dio3os antisense oligonucleotide

Dio3os antisense oligonucleotide is a preclinical-stage antisense oligonucleotide (ASO) therapy designed to target and silence the long non-coding RNA (lncRNA) Dio3os (Dio3 opposite strand). Developed by researchers at the University of Alabama at Birmingham (UAB), this therapeutic candidate is designed to disrupt the function of Dio3os, which acts as a chromatin-associated regulator. In estrogen receptor-positive (ER+) breast cancer, particularly in bone metastasis, Dio3os is upregulated and recruits the nucleosome remodeling and deacetylase (NuRD) complex containing HDAC1 to the promoters of oncogenic and metabolic regulators (such as MYC and lactate dehydrogenase), promoting tumor growth, metabolic reprogramming (aerobic glycolysis), and aromatase inhibitor (AI) resistance. By targeting exon-specific regions (exons 2–3) of Dio3os, the ASO disrupts its interaction with HDAC1, suppresses oncogenic transcriptional programs, and restores tumor suppressor activity. Additionally, because Dio3os activates Dio3 expression in cis while repressing osteoblast differentiation in trans, silencing Dio3os has been shown to enhance bone formation, offering a dual-action therapeutic strategy to both suppress metastatic tumor progression and treat skeletal disorders or bone loss.

Other names

Dio3os ASODio-3os ASODio 3os ASODio3os antisense oligonucleotidesDio-3os antisense oligonucleotidesDio 3os antisense oligonucleotidesantisense oligonucleotides targeting Dio3os